Pivotal role of leptin-hypothalamus signaling in the etiology of diabetes uncovered by gene therapy: A new therapeutic intervention

Gene Therapy

Volumn 18, Issue 4, 2011, Pages 319-325

  Kalra, S P ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

diabetes; hyperglycemia; hypothalamus; leptin; neural signaling

Indexed keywords

LEPTIN; PARVOVIRUS VECTOR;

DRUG EFFECT; GENE DELIVERY SYSTEM; GENE EXPRESSION; GENE THERAPY; HUMAN; HYPOTHALAMUS; INSULIN DEPENDENT DIABETES MELLITUS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; REVIEW; RISK FACTOR;

ANIMALS; DIABETES MELLITUS; GENE THERAPY; HUMANS; HYPERGLYCEMIA; HYPOTHALAMUS; LEPTIN; RATS; SIGNAL TRANSDUCTION; TRANSGENES;

ADENO-ASSOCIATED VIRUS; ADENOVIRIDAE; PRIMATES; RODENTIA;

EID: 79953792704     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2010.164     Document Type: Review

References (104)

1. Grundy SM. Obesity, metabolic syndrome, and cardiovascular disease. J Clin Endo-crinol Metab 2004; 89: 2595-2600. (Pubitemid 38766337)
2. Kahn SE, Hull RL, Utzschneider KM. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature 2006; 444: 840-846. (Pubitemid 46024990)
3. Lazar MA. How obesity causes diabetes: not a tall tale. Science 2005; 307: 373-375.
4. Whitmer RA, Gustafson DR, Barrett-Connor E, Haan MN, Gunderson EP, Yaffe K. Central obesity and increased risk of dementia more than three decades later. Neurology 2008; 71: 1057-1064.
5. Kalra SP. Increased leptin supply to hypothalamus by gene therapy confers life-long benefits on energy homeostasis, disease cluster of metabolic syndrome-diabetes type 1 and 2, dyslipidemia and cardiovascular ailments-and bone remodeling. In: Shioda S, Homma I, Kato N (eds). Transmitters and modulators in health and disease. Springer: Tokyo, 2009, pp 19-30.
6. Santamaria P. The long and winding road to understanding and conquering type 1 diabetes. Immunity 2010; 32: 437-445.
7. Kalra SP. Central leptin gene therapy ameliorates diabetes type 1 and 2 through two independent hypothalamic relays; a benefit beyond weight and appetite regulation. Peptides 2009; 30: 1957-1963.
8. Carr MC, Brunzell JD. Abdominal obesity and dyslipidemia in the metabolic syndrome: importance of type 2 diabetes and familial combined hyperlipidemia in coronary artery disease risk. J Clin Endocrinol Metab 2004; 89: 2601-2607. (Pubitemid 38766338)
9. Lewis GF, Carpentier A, Adeli K, Giacca A. Disordered fat storage and mobilization in the pathogenesis of insulin resistance and type 2 diabetes. Endocr Rev 2002; 23: 201-229. (Pubitemid 34299024)
10. Kalra SP, Kalra PS. Neuroendocrine control of energy homeostasis: update on new insights. Prog Brain Res 2010; 181: 17-33.
11. Robertson RP, Kendall DM, Seaquist ER. Diabetes: strategies to prevent the type 2 diabetes mellitus epidemic. Nat Rev Endocrinol 2010; 6: 128-129.
12. Bonow RO, Gheorghiade M. The diabetes epidemic: a national and global crisis. Am J Med 2004; 116: 2S-10S. (Pubitemid 38333036)
13. Kahn BB, Flier JS. Obesity and insulin resistance. J Clin Invest 2000; 106: 473-481. (Pubitemid 30666380)
14. Kalra PS, Kalra SP. Obesity and metabolic syndrome: long-term benefits of central leptin gene therapy. In: Prous JR (ed). Drugs of Today. Prous Science: Barcelona, Spain, 2002, pp 745-757. (Pubitemid 36090912)
15. Smyth S, Heron A. Diabetes and obesity: the twin epidemics. Nat Med 2006; 12: 75-80. (Pubitemid 43050080)
16. Friedman JM. Leptin at 14 y of age: an ongoing story. Am J Clin Nutr 2009; 89: 973S-979S.
17. Slyper AH. The pediatric obesity epidemic: causes and controversies. J Clin Endo-crinol Metab 2004; 89: 2540-2547. (Pubitemid 38766329)
18. Stein CJ, Colditz GA. The epidemic of obesity. J Clin Endocrinol Metab 2004; 89: 2522-2525. (Pubitemid 38766327)
19. Olshansky SJ, Passaro DJ, Hershow RC, Layden J, Carnes BA, Brody J et al. A potential decline in life expectancy in the United States in the 21st century. N Engl J Med 2005; 352: 1138-1145. (Pubitemid 40365358)
20. Cummings DE, Overduin J, Foster-Schubert KE. Gastric bypass for obesity: mechanisms of weight loss and diabetes resolution. J Clin Endocrinol Metab 2004; 89: 2608-2615. (Pubitemid 38766339)
21. Clifton P. Diabetes: treatment of type 2 diabetes mellitus with bariatric surgery. Nat Rev Endocrinol 2010; 6: 191-193.
22. McKnight SL. WAT-free mice: diabetes without obesity. Genes Dev 1998; 12: 3145-3148. (Pubitemid 28496258)
23. Farooqi IS, ORahilly S. Leptin: a pivotal regulator of human energy homeostasis. Am J Clin Nutr 2009; 89: 980S-984S.
24. Ogawa Y, Masuzaki H, Hosoda K, Aizawa-Abe M, Suga J, Suda M et al. Increased glucose metabolism and insulin sensitivity in transgenic skinny mice overexpressing leptin. Diabetes 1999; 48: 1822-1829. (Pubitemid 29415203)
25. Paz-Filho G, Esposito K, Hurwitz B, Sharma A, Dong C, Andreev V et al. Changes in insulin sensitivity during leptin replacement therapy in leptin-deficient patients. Am J Physiol Endocrinol Metab 2008; 295: E1401-E1408.
26. Shimomura I, Hammer RE, Ikemoto S, Brown MS, Goldstein JL. Leptin reverses insulin resistance and diabetes mellitus in mice with congenital lipodystrophy. Nature 1999; 401: 73-76.
27. Ebihara K, Kusakabe T, Hirata M, Masuzaki H, Miyanaga F, Kobayashi N et al. Efficacy and safety of leptin-replacement therapy and possible mechanisms of leptin actions in patients with generalized lipodystrophy. J Clin Endocrinol Metab 2007; 92: 532-541.
28. Petersen KF, Oral EA, Dufour S, Befroy D, Ariyan C, Yu C et al. Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy. J Clin Invest 2002; 109: 1345-1350. (Pubitemid 34546899)
29. Banting FG, Best CH. Pancreatic extracts 1922. J Lab Clin Med 1990; 115: 254-272.
30. Owens DR, Zinman B, Bolli GB. Insulins today and beyond. Lancet 2001; 358: 739-746. (Pubitemid 32823407)
31. Taubes G. Diabetes. paradoxical effects of tightly controlled blood sugar. Science 2008; 322: 365-367.
32. Carrascosa JM, Ros M, Andres A, Fernandez-Agullo T, Arribas C. Changes in the neuroendocrine control of energy homeostasis by adiposity signals during aging. Exp Gerontol 2009; 44: 20-25.
33. Kalra SP, Dube MG, Pu S, Xu B, Horvath TL, Kalra PS. Interacting appetite-regulating pathways in the hypothalamic regulation of body weight. Endocr Rev 1999; 20: 68-100. (Pubitemid 29092036)
34. Dietrich MO, Horvath TL. Feeding signals and brain circuitry. Eur J Neurosci 2009; 30: 1688-1696.
35. Kalra SP, Bagnasco M, Otukonyong EE, Dube MG, Kalra PS. Rhythmic, reciprocal ghrelin and leptin signaling: new insight in the development of obesity. Regul Pept 2003; 111: 1-11. (Pubitemid 36254743)
36. Chinookoswong N, Wang JL, Shi ZQ. Leptin restores euglycemia and normalizes glucose turnover in insulin- deficient diabetes in the rat. Diabetes 1999; 48: 1487-1492. (Pubitemid 29297316)
37. Hidaka S, Yoshimatsu H, Kondou S, Tsuruta Y, Oka K, Noguchi H et al. Chronic central leptin infusion restores hyperglycemia independent of food intake and insulin level in streptozotocin-induced diabetic rats. FA S E B J 2002; 16: 509-518. (Pubitemid 34273234)
38. Lin CY, Higginbotham DA, Judd RL, White BD. Central leptin increases insulin sensitivity in streptozotocin-induced diabetic rats. Am J Physiol Endocrinol Metab 2002; 282: E1084-E1091. (Pubitemid 34654723)
39. Otukonyong EE, Dube MG, Torto R, Kalra PS, Kalra SP. Central leptin differentially modulates ultradian secretory patterns of insulin, leptin and ghrelin independent of effects on food intake and body weight. Peptides 2005; 26: 2559-2566. (Pubitemid 41676732)
40. Otukonyong EE, Dube MG, Torto R, Kalra PS, Kalra SP. High fat diet-induced ultradian leptin and insulin hypersecretion and ghrelin is absent in obesity-resistant rats. Obes Res 2005; I13: 991-999.
41. Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM. Positional cloning of the mouse obese gene and its human homologue. Nature 1994; 372: 425-432. (Pubitemid 24365442)
42. Kalra SP. Central leptin insufficiency syndrome: an interactive etiology for obesity, metabolic and neural diseases and for designing new therapeutic interventions. Peptides 2008; 29: 127-138. (Pubitemid 350266118)
43. Kastin AJ, Pan W. Dynamic regulation of leptin entry into brain by the blood-brain barrier. Regul Pept 2000; 92: 37-43.
44. Kastin AJ, Pan W, Maness LM, Koletsky RJ, Ernsberger P. Decreased transport of leptin across the blood-brain barrier in rats lacking the short form of the leptin receptor. Peptides 1999; 20: 1449-1453. (Pubitemid 30069891)
45. Scott MM, Lachey JL, Sternson SM, Lee CE, Elias CF, Friedman JM et al. Leptin targets in the mouse brain. J Comp Neurol 2009; 514: 518-532.
46. Kalra SP. Disruption in the leptin-NPY link underlies the pandemic of diabetes and metabolic syndrome:new therapeutic approaches. Nutrition 2008; 24: 820-826.
47. Bartness TJ, Kay Song C, Shi H, Bowers RR, Foster MT. Brain-adipose tissue cross talk. Proc Nutr Soc 2005; 64: 53-64. (Pubitemid 40685752)
48. Kreier F, Kap YS, Mettenleiter TC, Van Heijningen C, Van der Vliet J, Kalsbeek A et al. Tracing from fat tissue, liver, and pancreas: a neuroanatomical framework for the role of the brain in type 2 diabetes. Endocrinology 2006; 147: 1140-1147. (Pubitemid 43244345)
49. Uyama N, Geerts A, Reynaert H. Neural connections between the hypothalamus and the liver. Anat Rec A Discov Mol Cell Evol Biol 2004; 280: 808-820. (Pubitemid 39330960)
50. Buijs RM, Chun SJ, Niijima A, Romijn HJ, Nagai K. Parasympathetic and sympathetic control of the pancreas: a role for the suprachiasmatic nucleus and other hypothalamic centers that are involved in the regulation of food intake. J Comp Neurol 2001; 431: 405-423. (Pubitemid 32178945)
51. Pu S, Dube MG, Kalra SP, Kalra PS. Permanent interruption of information flow between hypothalamus and hindbrain produces obesity accompanied by a selective dark-phase hyperphagia and hyperinsulinemia. 33rd Annual Society for Neuro-science Meeting. Society for Neuroscience: New Orleans, LA, 2003, pp W-33, Abstract no. 831.837.
52. Lee JH, Chan JL, Sourlas E, Raptopoulos V, Mantzoros CS. Recombinant methionyl human leptin therapy in replacement doses improves insulin resistance and metabolic profile in patients with lipoatrophy and metabolic syndrome induced by the highly active antiretroviral therapy. J Clin Endocrinol Metab 2006; 91: 2605-2611. (Pubitemid 44024625)
53. Park JY, Chong AY, Cochran EK, Kleiner DE, Haller MJ, Schatz DA et al. Type 1 diabetes associated with acquired generalized lipodystrophy and insulin resistance: the effect of long-term leptin therapy. J Clin Endocrinol Metab 2008; 93: 26-31.
54. Boghossian S, Dube MG, Torto R, Kalra PS, Kalra SP. Hypothalamic clamp on insulin release by leptin-transgene expression. Peptides 2006; 27: 3245-3254. (Pubitemid 44738167)
55. Ueno N, Dube MG, Inui A, Kalra PS, Kalra SP. Leptin modulates orexigenic effects of ghrelin and attenuates adiponectin and insulin levels and selectively the dark-phase feeding as revealed by central leptin gene therapy. Endocrinology 2004; 145: 4176-4184. (Pubitemid 39120566)
56. Ueno N, Inui A, Kalra SP, Kalra PS. Leptin transgene expression in the hypothalamus enforces euglycemia in diabetic, insulin-deficient nonobese Akita mice and leptin-deficient obese ob/ob mice. Peptides 2006; 27: 2332-2342. (Pubitemid 44189608)
57. Bluher S, Shah S, Mantzoros CS. Leptin deficiency: clinical implications and opportunities for therapeutic interventions. J Investig Med 2009; 57: 784-788.
58. Brennan AM, Lee JH, Tsiodras S, Chan JL, Doweiko J, Chimienti SN et al. r-metHuLeptin improves highly active antiretroviral therapy-induced lipoatrophy and the metabolic syndrome, but not through altering circulating IGF and IGF-binding protein levels: observational and interventional studies in humans. Eur J Endocrinol 2009; 160: 173-176.
59. Mulligan K, Khatami H, Schwarz JM, Sakkas GK, DePaoli AM, Tai VW et al. The effects of recombinant human leptin on visceral fat, dyslipidemia, and insulin resistance in patients with human immunodeficiency virus-associated lipoatrophy and hypoleptinemia. J Clin Endocrinol Metab 2009; 94: 1137-1144.
60. Cohen P, Zhao C, Cai X, Montez JM, Rohani SC, Feinstein P et al. Selective deletion of leptin receptor in neurons leads to obesity. J Clin Invest 2001; 108: 1113-1121. (Pubitemid 32995369)
61. Keen-Rhinehart E, Kalra SP, Kalra PS. AAV mediated leptin receptor installation improves energy balance and the reproductive status of obese female Koletsky rats. Peptides 2005; 26: 2567-2578. (Pubitemid 41676733)
62. Banks WA, DiPalma CR, Farrell CL. Impaired transport of leptin across the blood-brain barrier in obesity. Peptides 1999; 20: 1341-1345.
63. Banks WA, Farr SA, Morley JE. The effects of high fat diets on the blood-brain barrier transport of leptin: failure or adaptation? Physiol Behav 2006; 88: 244-248.
64. Banks WA, Farrell CL. Impaired transport of leptin across the blood-brain barrier in obesity is acquired and reversible. Am J Physiol Endocrinol Metab 2003; 285: E10-E15. (Pubitemid 36736356)
65. Burguera B, Couce ME, Curran GL, Jensen MD, Lloyd RV, Cleary MP et al. Obesity is associated with a decreased leptin transport across the blood-brain barrier in rats. Diabetes 2000; 49: 1219-1223. (Pubitemid 30439098)
66. Caro JF, Kolaczynski JW, Nyce MR, Ohannesian JP, Opentanova I, Goldman WH et al. Decreased cerebrospinal-fluid/serum leptin ratio in obesity: a possible mechanism for leptin resistance. Lancet 1996; 348: 159-161. (Pubitemid 26238099)
67. Ziylan YZ, Baltaci AK, Mogulkoc R. Leptin transport in the central nervous system. Cell Biochem Funct 2009; 27: 63-70.
68. Kastin AJ, Pan W. Intranasal leptin: blood-brain barrier bypass (BBBB) for obesity? Endocrinology 2006; 147: 2086-2087.
69. Kalra SP. Circumventing leptin resistance for weight control. Proc Natl Acad Sci USA 2001; 98: 4279-4281. (Pubitemid 32294964)
70. Kalra SP, Kalra PS. Gene transfer technology: a preventive neurotherapy to curb obesity, ameliorate metabolic syndrome and extend life-expectancy. Trends Pharmacol Sci 2005; 26: 488-495. (Pubitemid 41338558)
71. Carter BJ, Burstein H. Adeno-associated virus and AAV vectors for gene delivery. In: Templeton-Smith N (ed). Theruapeutics Mechanisms and Strategies. Marcel Dekker: New York, NY, 2004, pp 71-1011.
72. Dhillon H, Ge Y, Minter RM, Prima V, Moldawer LL, Muzyczka N et al. Long-term differential modulation of genes encoding orexigenic and anorexigenic peptides by leptin delivered by rAAV vector in ob/ob mice. Relationship with body weight change. Regul Pept 2000; 92: 97-105.
73. Dhillon H, Kalra SP, Kalra PS. Dose-dependent effects of central leptin gene therapy on genes that regulate body weight and appetite in the hypothalamus. Mol Ther 2001; 4: 139-145. (Pubitemid 32776505)
74. Dhillon H, Kalra SP, Prima V, Zolotukhin S, Scarpace PJ, Moldawer LL et al. Central leptin gene therapy suppresses body weight gain, adiposity and serum insulin without affecting food consumption in normal rats: a long-term study. Regul Pept 2001; 99: 69-77. (Pubitemid 32522533)
75. Miyanaga F, Ogawa Y, Ebihara K, Hidaka S, Tanaka T, Hayashi S et al. Leptin as an adjunct of insulin therapy in insulin-deficient diabetes. Diabetologia 2003; 46: 1329-1337. (Pubitemid 37297202)
76. Briley LP, Szczech LA. Leptin and renal disease. Semin Dial 2006; 19: 54-59. (Pubitemid 43479011)
77. Correia MLG, Rahmouni K. Role of leptin in the cardiovascular and endocrine complications of metabolic syndrome. Diabetes, Obes Metab 2006; 8: 603-610. (Pubitemid 44515557)
78. Chen G, Koyama K, Yuan X, Lee Y, Zhou YT, ODoherty R et al. Disappearance of body fat in normal rats induced by adenovirus-mediated leptin gene therapy. Proc Natl Acad Sci USA 1996; 93: 14795-14799. (Pubitemid 26419048)
79. Koyama K, Shimabukuro M, Chen G, Wang MY, Lee Y, Kalra PS et al. Resistance to adenovirally induced hyperleptinemia in rats. Comparison of ventromedial hypo-thalamic lesions and mutated leptin receptors. J Clin Invest 1998; 102: 728-733. (Pubitemid 28399605)
80. Muzzin P, Cusin I, Charnay Y, Rohner-Jeanrenaud F. Single intracerebroventricular bolus injection of a recombinant adenovirus expressing leptin results in reduction of food intake and body weight in both lean and obese Zucker fa/fa rats. Regul Pept 2000; 92: 57-64.
81. Murphy JE, Zhou S, Giese K, Williams LT, Escobedo JA, Dwarki VJ. Long-term correction of obesity and diabetes in genetically obese mice by a single intramuscular injection of recombinant adeno-associated virus encoding mouse leptin. Proc Natl Acad Sci USA 1997; 94: 13921-13926. (Pubitemid 28009685)
82. Bagnasco M, Dube MG, Kalra PS, Kalra SP. Evidence for the existence of distinct central appetite and energy expenditure pathways and stimulation of ghrelin as revealed by hypothalamic site-specific leptin gene therapy. Endocrinology 2002; 143: 4409-4421. (Pubitemid 35239575)
83. Bagnasco M, Dube MG, Katz A, Kalra PS, Kalra SP. Leptin expression in hypothalamic PVN reverses dietary obesity and hyperinsulinemia but stimulates ghrelin. Obes Res 2003; 11: 1463-1470. (Pubitemid 41127330)
84. Gao G, Vandenberghe LH, Wilson JM. New recombinant serotypes of AAV vectors. Curr Gene Ther 2005; 5: 285-297. (Pubitemid 40895013)
85. Taymans JM, Vandenberghe LH, Haute CV, Thiry I, Deroose CM, Mortelmans L et al. Comparative analysis of adeno-associated viral vector serotypes 1, 2, 5, 7, and 8 in mouse brain. Hum Gene Ther 2007; 18: 195-206. (Pubitemid 46626459)
86. Beretta E, Dube MG, Kalra PS, Kalra SP. Long-term suppression of weight gain, adiposity, and serum insulin by central leptin gene therapy in prepubertal rats: effects on serum ghrelin and appetite-regulating genes. Pediatr Res 2002; 52: 189-198. (Pubitemid 34827239)
87. Boghossian S, Lecklin AH, Torto R, Kalra PS, Kalra SP. Suppression of fat deposition for the life time of rodents with gene therapy. Peptides 2005; 26: 1512-1519. (Pubitemid 41021489)
88. Boghossian S, Ueno N, Dube MG, Kalra P, Kalra S. Leptin gene transfer in the hypothalamus enhances longevity in adult monogenic mutant mice in the absence of circulating leptin. Neurobiol Aging 2007; 28: 1594-1604. (Pubitemid 47238536)
89. Wang J, Takeuchi T, Tanaka S, Kubo SK, Kayo T, Lu D et al. A mutation in the insulin 2 gene induces diabetes with severe pancreatic beta-cell dysfunction in the Mody mouse. J Clin Invest 1999; 103: 27-37. (Pubitemid 29031160)
90. Malhotra A, Vashistha H, Yadav VS, Dube MG, Kalra SP, Abdellatif M et al. Inhibition of p66ShcA redox activity in cardiac muscle cells attenuates hyperglycemia-induced oxidative stress and apoptosis. Am J Physiol Heart Circ Physiol 2009; 296: H380-H388.
91. Kamohara S, Burcelin R, Halaas JL, Friedman JM, Charron MJ. Acute stimulation of glucose metabolism in mice by leptin treatment. Nature 1997; 389: 374-377. (Pubitemid 27415217)
92. Wang JL, Chinookoswong N, Scully S, Qi M, Shi ZQ. Differential effects of leptin in regulation of tissue glucose utilization in vivo. Endocrinology 1999; 140: 2117-2124. (Pubitemid 30636450)
93. Yu X, Park BH, Wang MY, Wang ZV, Unger RH. Making insulin-deficient type 1 diabetic rodents thrive without insulin. Proc Natl Acad Sci USA 2008; 105: 14070-14075.
94. Wang MY, Chen L, Clark GO, Lee Y, Stevens RD, Ilkayeva OR et al. Leptin therapy in insulin-deficient type I diabetes. Proc Natl Acad Sci USA 2010; 107: 4813-4819.
95. Kraus D, Herman MA, Kahn BB. Leveraging leptin for type I diabetes? Proc Natl Acad Sci USA 2010; 107: 4793-4794.
96. Kojima S, Asakawa A, Amitani H, Sakoguchi T, Ueno N, Inui A et al. Central leptin gene therapy, a substitute for insulin therapy to ameliorate hyperglycemia and hyperphagia, and promote survival in insulin-deficient diabetic mice. Peptides 2009; 30: 962-966.
97. Dube MG, Beretta E, Dhillon H, Ueno N, Kalra PS, Kalra SP. Central leptin gene therapy blocks high fat diet-induced weight gain, hyperleptinemia and hyper-insulinemia: effects on serum ghrelin levels. Diabetes 2002; 51: 1729-1736. (Pubitemid 34564284)
98. Lecklin AH, Dube MG, Torto R, Kalra PS, Kalra SP. Perigestational suppression of weight gain with central leptin gene therapy results in lower weight F1 generation. Peptides 2005; 26: 1176-1187. (Pubitemid 40798074)
99. Dube MG, Torto R, Kalra SP. Increased leptin expression selectively in the hypo-thalamus suppresses inflammatory markers CRP and IL-6 in leptin-deficient diabetic obese mice. Peptides 2008; 29: 593-598.
100. Iwaniec UT, Boghossian S, Lapke PD, Turner RT, Kalra SP. Central leptin gene therapy corrects skelet al abnormalities in leptin-deficient ob/ob mice. Peptides 2007; 28: 1012-1019. (Pubitemid 46654437)
101. Kalra SP, Dube MG, Iwaniec UT. Leptin increases osteoblast-specific osteocalcin release through a hypothalamic relay. Peptides 2009; 30: 967-973.
102. Kaplitt MG, Feigin A, Tang C, Fitzsimons HL, Mattis P, Lawlor PA et al. Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinsons disease: an open label, phase I trial. Lancet 2007; 369: 2097-2105. (Pubitemid 46935946)
103. Mandel RJ, Burger C. Clinical trials in neurological disorders using AAV vectors: promises and challenges. Curr Opin Mol Ther 2004; 6: 482-490. (Pubitemid 39386597)
104. Mueller C, Flotte TR. Clinical gene therapy using recombinant adeno-associated virus vectors. Gene Therapy 2008; 15: 858-863. (Pubitemid 351712619)